Cubicin Endocarditis Trial Shows Improved Renal Safety Over Vancomycin
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pivotal data for Cubist's Cubicin treatment of endocarditis/bacteremia show comparable efficacy to standard care with superior renal safety, the firm reported Dec. 16
You may also be interested in...
Cubist To Seek Cubicin sNDA Priority Review For Endocarditis, Bacteremia
Cubist plans to request a priority review for an sNDA it will submit by year-end for use of its Cubicin antibiotic for endocarditis and bacteremia
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product